Biotech Co.* |
Pharma Co. |
Product |
Terms/Details (Date) |
Affibody AB* |
Funakoshi Co. Ltd. (Japan) |
Funakoshi will promote and distribute Affibody research reagents in Japan |
Terms of the deal were not disclosed (10/4) |
Alpha |
GE Healthcare (UK) |
Alpha Innotech will develop a line of imaging systems for GE |
The products will be sold worldwide under the GE brand; terms of the deal were not disclosed (9/2) |
Ambion Inc.* |
GE Healthcare (UK) |
GE will manufacture microRNA microarrays for Ambion |
GE will use its CodeLink Bioarray technology in the license supply agreement; terms of the deal were not disclosed (9/29) |
Auxilium |
DPT Laboratories |
They extended deal for the manufacturing of Testim through 2010 |
The deal for manufacturing Auxilium's Testim was set to expire in 2005; DPT will manufacture it under undisclosed terms (9/21) |
Cephalon Inc.(CEPH) |
McNeil Consumer & Specialty Pharmaceuticals |
Deal to co-promote Attenace (modafinil), for which an sNDA has been field with the FDA for treating attention deficit/ hyperactivity disorder |
Cephalon will pay McNeil commission fees on sales of Attenace in the deal, which will last up to three years(9/1) |
Codexis Inc.* |
Arch Pharmalabs Ltd. (India) |
Codexis will use its Molecular- Breeding technology to manufacture an undisclosed compound for Arch |
Codexis is entitled to up-front and milestone payments from Arch, a generic pharmaceutical company (10/11) |
Codexis Inc.* |
Matrix Laboratories Ltd. (India) |
Deal to develop a process for the manufacture of an undisclosed drug |
Codexis is entitled to R&D funding, milestone payments and royalties; it will use its MolecularBreeding technology in the effort (10/11) |
CombiMatrix |
VWR International Inc. |
VWR will distribute Custom- Arrays and CatalogArrays |
Terms of the global distribution agreement were not disclosed (9/13) |
Cortex |
Vita Inc. (Japan) |
Vita will market Cortex products in Japan |
The deal covers the MagaZorb Nucleic Acid Isolation Kits and associated reagents, and magnetic separation and immunoreagent products (10/11) |
Enobia |
Laureate Pharma Inc. |
Deal for the process development and manufacture of Enobia's recombinant enzyme sPHEX Metallo Peptidase |
Phase I trials are expected to start in 3Q:06; terms of the deal were not disclosed (9/21) |
ExonHit |
Agilent Technologies Inc. |
Agilent will distribute ExonHit's SpliceArrays technology |
SpliceArrays is a new generation of micro- arrays to detect alternative splicing (9/1) |
Hemispherx |
HollisterStier Laboratories |
They signed a letter of intent for the contract manufacturing of Hemispherx's Ampligen |
Terms of the deal were not disclosed (10/10) |
IBEX |
Seikagaku Corp. (Japan) and Prozyme Inc. |
Seikagaku and Prozyme will market IBEX enzymes to customers in the worldwide research community |
Terms of the deal with Prozyme and Seikagaku subsidiary Associates of Cape Cod Inc. were not disclosed (9/20) |
ImmunoGen |
Diosynth Biotechnology (unit of NV Organon) |
Diosynth will manufacture ImmunoGen's huN901 antibody |
The antibody will be used in ImmunoGen's huN901-DM1 anticancer compound (10/6) |
InSite Vision |
Cardinal Health |
Cardinal will manufacture commercial supplies of AzaSite (1% azithromycin) |
Cardinal has been manufacturing the anti- infective for clinical trials; terms were not disclosed (9/22) |
Mesoblast Ltd. |
Cambrex Corp. |
Deal for large-scale production of Mesoblast's adult stem cells |
Cambrex will produce clinical-grade cells under undisclosed terms (9/20) |
NeoPharm |
Diosynth Biotechnology (unit of NV Organon) |
They amended manufacturing deal covering NeoPharm's IL13-PE38QQR |
Deal covers manufacturing following the ongoing Phase III trial in brain cancer if NeoPharm moves ahead with BLA filing (9/21) |
Peptech Ltd. |
Undisclosed |
Deal for the manufacturing of Peptech's anti-TNF domain antibody |
The unnamed company will manufacture the antibody to GMP standards (9/12) |
ProtoKinetix |
Undisclosed company |
Deal to study ProtoKinetix's AAGP for the stabilization of the partner's vaccines |
AAGP is a synthetic antifreeze glycoprotein; terms of the deal were not disclosed (10/6) |
Samaritan |
Norbrook Laboratories S.R.O. (Northern Ireland) |
Norbrook would supply raw formulation material to Samaritan's manufacturing partner upon approval of SP-01A |
SP-01A is Samaritan's lead HIV drug; its manufacturing partner is Pharmaplaz (9/27) |
Vernalis plc |
Diosynth Biotechnology (unit of NV Organon) V10153 for Phase III trials |
Deal for the process development, scale-up and manufacturing of Vernalis' |
Diosynth will manufacture the thrombolytic agent under undisclosed terms (9/22) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. |